Immunofluorescence Assay Market Size - By Product (Antibodies, Kits & Reagents, Instruments, Consumables & Accessories), Type (Indirect & Direct Immunofluorescence), Application (Cancer, Infectious Diseases), End-use & Forecast, 2024 - 2032

PUBLISHED: June 12, 2024

PAGES: 167 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Immunofluorescence assay market size is anticipated to witness 5.1% CAGR between 2024 and 2032 driven by the increasing prevalence of chronic diseases along with the rising demand for accurate and early diagnostic tools. Immunofluorescence assays (IFA) are crucial for detecting and quantifying specific biomarkers associated with diseases, such as cancer, autoimmune disorders, and infectious diseases. As the global incidence of these conditions is continuing to rise, there is growing need for reliable diagnostic techniques to provide precise and timely information. As per WHO, by 2050, chronic diseases, such as cardiovascular conditions, cancer, diabetes, and respiratory illnesses are projected to account 90 million deaths annually.

Innovations in fluorescent dyes, antibodies, and detection systems will also enhance the performance and versatility of IFAs for more detailed and accurate analyses. The increasing investments in R&D activities by pharmaceutical and biotechnology companies for fostering the creation of novel immunofluorescence solutions with enhanced capabilities will drive the market growth.

The overall industry is classified into product, type, application, end-use and region.

Based on product, the IFA market from the instruments segment is slated to witness significant growth during 2024-2032 due to the critical role that advanced imaging and detection systems play in enhancing the accuracy and efficiency of these assays. Sophisticated instruments, such as fluorescence microscopes, automated imaging systems, and specialized detectors are essential for visualizing and quantifying fluorescent signals with high precision.

Immunofluorescence assay industry size from the infectious disease application segment is anticipated to witness substantial growth through 2032 owing to the increasing need for rapid and precise diagnostic methods to identify and manage infectious pathogens. Immunofluorescence assays are highly effective in detecting specific antigens associated with a wide range of infectious diseases, including viral, bacterial, and parasitic infections.

Asia Pacific immunofluorescence assay market is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding healthcare infrastructure and hefty investments in R&D activities. Rapid advancements in biotechnology and the strong emphasis on enhancing diagnostic capabilities are fueling the demand for sophisticated immunofluorescence assays. The growing burden of infectious and chronic diseases, coupled with the rising healthcare expenditure and government initiatives to improve disease management will further stimulate the regional market growth.

Product Code: 9818

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Technological advancements in immunofluorescence assays
  - 3.2.1.3 Growing research and development activities
  - 3.2.1.4 Rising adoption of point-of-care testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of instruments
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
3.7 Pricing analysis, 2023
- 3.7.1 By region
- 3.7.2 By key player
3.8 Future market trends
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antibodies
5.3 Kits and reagents
5.4 Instruments
5.5 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Indirect immunofluorescence
6.3 Direct immunofluorescence

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Infectious diseases
7.4 Cardiovascular diseases
7.5 Autoimmune diseases
7.6 Other diseases

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Academic & research institutes
8.3 Pharmaceutical & biotechnology companies
8.4 Contract research organizations
8.5 Hospitals & diagnostic centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa